A Chemotherapy-Free Regimen of Tucatinib and Trastuzumab Shows Antitumour Activity with Durable Responses in Patients with HER2-mutated MBC By Ogkologos - January 29, 2025 727 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SGNTUC-019 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR Helping Kids with Cancer Speak for the Supportive Care They Need December 13, 2024 7 Steps for Developing Microhabits During Cancer That Can Improve Your... November 2, 2023 Talazoparib Beyond BRCA Prospective Study Identifies the Sensitivity of gPALB2-Associated Breast... October 25, 2022 FDA Approves Asparaginase Erwinia Chrysanthemi (Recombinant)-rywn for Acute Lymphoblastic Leukaemia and... July 13, 2021 Load more HOT NEWS Regular Exercise May Help Guard Breast Cancer Patients From Chemo Brain Helping Dogs—and Humans—with Cancer: NCI’s Comparative Oncology Studies Death Rates from Lung Cancer will Fall Overall in the EU... Can Cancer Prevention Be Better Integrated into Primary Care?
